Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in its ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve ...

Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM. Type ...

In trading on Wednesday, shares of Beam Therapeutics Inc (Symbol: BEAM) crossed above their 200 day moving average of $25.21, changing hands as high as $26.35 per share. Beam Therapeutics Inc ...

Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the ...

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...